Samus Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Boston MA United States (2011)

Organization Overview

First Clinical Trial
2011
NCT01269593
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Samus Therapeutics | Samus Therapeutics Consultant | Samus Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

124i-pu-ad (4 trials)

pu-h71 (4 trials)

Drugs in Phase 1 Trials (4)

124i puh71 (1 trial)

icapamespib (1 trial)

paclitaxel (taxol) (1 trial)

ruxolitinib (jakafi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Breast Neoplasms (Phase 1)

Dementia (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Motor Neuron Disease (Phase 2)

Polycythemia (Phase 1)

Polycythemia Vera (Phase 1)

Primary Myelofibrosis (Phase 1)

Sclerosis (Phase 2)

Thrombocythemia, Essential (Phase 1)

Thrombocytosis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 6